Lack of new drugs for tropical disease should not be accepted

doi:10.1136/bmj.321.7254.179/a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Michael Schull, president, Médecins Sans Frontières/Doctors Without Borders (Canada) (mjs@ices.on.ca)

Clinical Epidemiology Unit, Sunnybrook and Women's College Health Sciences Center, University of Toronto, Canada M4N 3M5

EDITOR—In their overview of recent advances in the treatment of common tropical infections Murray et al note the dramatic resurgence of African trypanosomiasis, which claims tens of thousands of lives annually in sub-Saharan Africa.1 They also describe the toxicity and increasing resistance associated with current drug regimens.

In their discussion of newer drugs to fight trypanosomiasis they remark that more effective drugs exist, though they are more costly and of …